Sun Pharma inks licensing pact with SPARC to commercialise medication in US market

SPARC submitted a new drug application (NDA) to the US Food and Drug Administration (US FDA) for the said product in February 2022.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/rem5Oyd
via IFTTT